Peregrine Pharmaceuticals has inked a definitive agreement to sell 8 million shares of common stock to an institutional investor for net proceeds of $6.7 million.
The funding will be used to advance Peregrine's three clinical trials, as well as support other preclinical studies, according to the Tustin, CA-based firm.
By AuntMinnie.com staff writers
June 24, 2005
Related Reading
Peregrine nets grant from Philip Morris, September 9, 2003
TNT gets clearance in China, August 13, 2003
Peregrine, Affitech team up, June 18, 2003
Peregrine regains Nasdaq compliance, June 12, 2003
Peregrine, Schering team up, January 7, 2003
Copyright © 2005 AuntMinnie.com
